CMA mediates resistance in breast cancer models

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Breast cancer (BC) remains a leading cause of cancer death in women, with chemoresistance posing a significant clinical challenge.
• Doxorubicin (Doxo) is a common chemotherapy agent, but its efficacy is limited by the development of resistance.
• Chaperone-mediated autophagy (CMA) plays a crucial role in cellular responses to chemotherapy, with LAMP-2A identified as a key mediator and potential biomarker.

Purpose of the Study:

• To investigate the role of CMA and LAMP-2A expression in breast cancer chemoresistance.
• To evaluate the therapeutic potential of targeting CMA and HIF-1α in overcoming treatment resistance.
• To explore synergistic drug combinations for improved breast cancer treatment efficacy.

Main Methods:

• Screening of breast cancer cell lines and patient tumors for Doxo effect and CMA activation via LAMP-2A analysis.
• Utilizing molecular silencing to elucidate the role of CMA in treatment response.
• Combining low-dose Doxo with TMZ or PX-478 (HIF-1α inhibitor) to assess synergistic cytotoxic effects.

Main Results:

• CMA activity was found to be critical for mediating breast cancer cell responsiveness to Doxo and TMZ.
• LAMP-2A expression levels varied across cell lines and tumor subtypes, correlating with patient survival rates.
• Inhibition of HIF-1α activity reversed TMZ resistance in breast cancer cells, and drug combinations demonstrated synergistic effects.

Conclusions:

• CMA activity is fundamental to treatment response in breast cancer, with LAMP-2A serving as a reliable prognostic biomarker.
• HIF-1α is a potential therapeutic target in BC, offering a strategy to develop more effective and less toxic drug combinations.
• Combining drugs targeting different molecular pathways can overcome chemoresistance, potentially reducing individual drug dosages.